• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRIAZOLAM Drug Record

  • Summary
  • Interactions
  • Claims
  • TRIAZOLAM chembl:CHEMBL646

    Alternate Names:

    U-33030
    HALCION
    KENTION
    TRIAZOLAM CIV
    TRIAZOLAM
    N05CD05
    TRIAZOLAMUM
    pubchem.compound:5556
    chembl:CHEMBL646
    drugbank:00897
    rxcui:10767
    chemidplus:28911-01-5

    Drug Info:

    Year of Approval 1982
    Drug Class hypnotics and sedatives
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications analgesic,sedative
    Drug Groups investigational
    Drug Categories agents causing muscle toxicity
    Drug Categories benzodiazepine hypnotics and sedatives
    Drug Categories benzodiazepines and benzodiazepine derivatives
    Drug Categories cytochrome p-450 cyp2c8 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 cyp3a7 substrates
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs that are mainly renally excreted
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories triazolobenzodiazepines
    (5 More Sources)

    Publications:

    Riss et al., 2008, Benzodiazepines in epilepsy: pharmacology and pharmacokinetics., Acta Neurol. Scand.
    Möhler et al., 2002, A new benzodiazepine pharmacology., J. Pharmacol. Exp. Ther.
    Filippakopoulos et al., 2012, Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family., Bioorg. Med. Chem.
    Zhu S et al., 2018, Structure of a human synaptic GABA<sub>A</sub> receptor., Nature
    Sigel E et al., 2012, Structure, function, and modulation of GABA(A) receptors., J Biol Chem
    Park et al., 1996, Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line., Glia
  • TRIAZOLAM   BRDT

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   BRD3

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   PBRM1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   BRD2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   GABRR2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial

  • TRIAZOLAM   GABRR3

    Interaction Score: 0.26

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial

  • TRIAZOLAM   KAT2B

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   GABRR1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial

  • TRIAZOLAM   BRD4

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   CREBBP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   TSPO

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8787774


    Sources:
    TEND TTD

  • TRIAZOLAM   GABRQ

    Interaction Score: 0.17

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRP

    Interaction Score: 0.15

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRE

    Interaction Score: 0.15

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRD

    Interaction Score: 0.15

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRG1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRB1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRB3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRA5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    positive modulator (activating)
    allosteric modulator
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • TRIAZOLAM   GABRA1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    ligand
    positive modulator (activating)
    allosteric modulator
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090 29950725 23038269


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • TRIAZOLAM   GABRB2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRG3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRA2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    positive modulator (activating)
    allosteric modulator
    potentiator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • TRIAZOLAM   GABRA3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    positive modulator (activating)
    allosteric modulator
    potentiator

    Interaction Info:
    Trial Name ARX-03, sufentanil + triazolam NanoTab
    Novel drug target Established target
    Direct Interaction? True

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • TRIAZOLAM   GABRA4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRA6

    Interaction Score: 0.12

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name ARX-03, sufentanil + triazolam NanoTab

    PMIDs:
    18384456 11752090


    Sources:
    TEND TdgClinicalTrial ChemblInteractions

  • TRIAZOLAM   GABRG2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes

    PMIDs:
    18384456 11752090


    Sources:
    TEND ChemblInteractions

  • TRIAZOLAM   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TRIAZOLAM   BAZ2B

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22137933


    Sources:
    DTC

  • TRIAZOLAM   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DrugBank: DB00897

    • Version: 5.1.7

    Alternate Names:
    TRIAZOLAM DrugBank Drug Name
    28911-01-5 CAS Number
    Alti-triazolam Tab 0.125mg Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Zhu S et al., 2018, Structure of a human synaptic GABA<sub>A</sub> receptor., Nature
    Sigel E et al., 2012, Structure, function, and modulation of GABA(A) receptors., J Biol Chem

  • TEND: TRIAZOLAM

    • Version: 01-August-2011

    Alternate Names:
    TRIAZOLAM Primary Drug Name

    Drug Info:
    Drug Class hypnotics and sedatives
    Year of Approval 1982

    Publications:

  • TdgClinicalTrial: TRIAZOLAM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic,sedative
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: TRIAZOLAM

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL646 ChEMBL Drug ID

    Drug Info:

    Publications:
    Filippakopoulos et al., 2012, Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family., Bioorg. Med. Chem.

  • GuideToPharmacology: 178103886

    • Version: 29-September-2020

    Alternate Names:
    TRIAZOLAM GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Triazolam

    • Version: 2020.06.01

    Alternate Names:
    D0U3LS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL646

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL646

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: triazolam

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2021-04-13